Please assess the completion status of the following clinical trial:

Trial Title: Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signage of a written informed consent~2. Age above 18 years~3. HCC unsuitable for resection~4. Child-Pugh A or B cirrhosis~5. Eastern Cooperative Oncology Group performance score 0 or 1~6. No previous treatment with liver resection, ablation, chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy),~7. HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology.~8. No extra-hepatic involvement on non-enhanced CT thorax and triphasic contrast enhanced CT abdomen.~9. No invasion of portal vein or hepatic vein~10. Massive expansive tumor morphology with measurable lesion on CT (characterized by well-defined spherical or globular configuration, with or without tumor capsule or satellite lesions)~11. Total tumor mass \< 50% liver volume~12. Size of any individual tumor \>10cm in largest dimension~Exclusion Criteria:~1. History of acute tumor rupture presenting with hemo-peritoneum~2. Biliary obstruction not amenable to percutaneous or endoscopic drainage~3. Child-Pugh C cirrhosis~4. History of hepatic encephalopathy~5. Intractable ascites not controllable by medical therapy~6. History of variceal bleeding within last 3 months~7. Serum total bilirubin level \> 50 umol/L~8. Serum albumin level \< 25g/L~9. INR \> 1.7~10. Serum creatinine level \> 150 mmol/L.~11. Infiltrative tumor morphology (characterized by ill- defined tumor margin and amorphous configuration) or diffuse tumor morphology (characterized by large number of small nodules)~12. Arterio-portal venous shunt affecting \>1 hepatic segment on CT~13. Arterial-hepatic venous shunt with hepatic vein opacified in arterial phase on CT

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACE for HCC of size >10cm (Type: OTHER): Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).